The heterogeneity of amyotrophic lateral sclerosis

A possible explanation of treatment failure

Ettore Beghi, Tiziana Mennini, Caterina Bendotti, Paolo Bigini, Giancarlo Logroscino, Adriano Chiò, Orla Hardiman, Douglas Mitchell, Robert Swingler, Bryan J. Traynor, Ammar Al-Chalabi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe clinical condition characterized by upper and lower motor neuron degeneration for which there is no truly effective treatment. The absence of an effective treatment can be explained in part by the complex and heterogeneous genetic, biochemical, and clinical features of ALS. While ALS accounts for the majority of the motor neuron diseases, the recognition of disease variants and mimic syndromes may lead to further insights into possible causes for the generality of ALS. From a biochemical perspective, the process of motor neuron degeneration is complex and the multifactorial influences and potential biomarkers of ALS have never been assessed in the light of the clinical heterogeneity of ALS. Several genes and environmental influences have been suggested as possible risk factors of ALS. A better understanding of interactions between these risk factors, potential biomarkers and heterogeneous clinical features may lead to more clearly defined pathological profiles among individuals or groups of ALS patients and in turn lead to more focused therapeutic trials.

Original languageEnglish
Pages (from-to)3185-3200
Number of pages16
JournalCurrent Medicinal Chemistry
Volume14
Issue number30
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Amyotrophic Lateral Sclerosis
Treatment Failure
Neurons
Biomarkers
Nerve Degeneration
Motor Neurons
Genes
Motor Neuron Disease
Molecular Biology
Therapeutics

Keywords

  • Amyotrophic lateral sclerosis
  • Biochemistry
  • Epidemiology
  • Genetics
  • Heterogeneity
  • Motor neuron disease

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

The heterogeneity of amyotrophic lateral sclerosis : A possible explanation of treatment failure. / Beghi, Ettore; Mennini, Tiziana; Bendotti, Caterina; Bigini, Paolo; Logroscino, Giancarlo; Chiò, Adriano; Hardiman, Orla; Mitchell, Douglas; Swingler, Robert; Traynor, Bryan J.; Al-Chalabi, Ammar.

In: Current Medicinal Chemistry, Vol. 14, No. 30, 12.2007, p. 3185-3200.

Research output: Contribution to journalArticle

Beghi, E, Mennini, T, Bendotti, C, Bigini, P, Logroscino, G, Chiò, A, Hardiman, O, Mitchell, D, Swingler, R, Traynor, BJ & Al-Chalabi, A 2007, 'The heterogeneity of amyotrophic lateral sclerosis: A possible explanation of treatment failure', Current Medicinal Chemistry, vol. 14, no. 30, pp. 3185-3200. https://doi.org/10.2174/092986707782793862
Beghi, Ettore ; Mennini, Tiziana ; Bendotti, Caterina ; Bigini, Paolo ; Logroscino, Giancarlo ; Chiò, Adriano ; Hardiman, Orla ; Mitchell, Douglas ; Swingler, Robert ; Traynor, Bryan J. ; Al-Chalabi, Ammar. / The heterogeneity of amyotrophic lateral sclerosis : A possible explanation of treatment failure. In: Current Medicinal Chemistry. 2007 ; Vol. 14, No. 30. pp. 3185-3200.
@article{f1a24089dd99473382fc68e531e8661e,
title = "The heterogeneity of amyotrophic lateral sclerosis: A possible explanation of treatment failure",
abstract = "Amyotrophic lateral sclerosis (ALS) is a severe clinical condition characterized by upper and lower motor neuron degeneration for which there is no truly effective treatment. The absence of an effective treatment can be explained in part by the complex and heterogeneous genetic, biochemical, and clinical features of ALS. While ALS accounts for the majority of the motor neuron diseases, the recognition of disease variants and mimic syndromes may lead to further insights into possible causes for the generality of ALS. From a biochemical perspective, the process of motor neuron degeneration is complex and the multifactorial influences and potential biomarkers of ALS have never been assessed in the light of the clinical heterogeneity of ALS. Several genes and environmental influences have been suggested as possible risk factors of ALS. A better understanding of interactions between these risk factors, potential biomarkers and heterogeneous clinical features may lead to more clearly defined pathological profiles among individuals or groups of ALS patients and in turn lead to more focused therapeutic trials.",
keywords = "Amyotrophic lateral sclerosis, Biochemistry, Epidemiology, Genetics, Heterogeneity, Motor neuron disease",
author = "Ettore Beghi and Tiziana Mennini and Caterina Bendotti and Paolo Bigini and Giancarlo Logroscino and Adriano Chi{\`o} and Orla Hardiman and Douglas Mitchell and Robert Swingler and Traynor, {Bryan J.} and Ammar Al-Chalabi",
year = "2007",
month = "12",
doi = "10.2174/092986707782793862",
language = "English",
volume = "14",
pages = "3185--3200",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "30",

}

TY - JOUR

T1 - The heterogeneity of amyotrophic lateral sclerosis

T2 - A possible explanation of treatment failure

AU - Beghi, Ettore

AU - Mennini, Tiziana

AU - Bendotti, Caterina

AU - Bigini, Paolo

AU - Logroscino, Giancarlo

AU - Chiò, Adriano

AU - Hardiman, Orla

AU - Mitchell, Douglas

AU - Swingler, Robert

AU - Traynor, Bryan J.

AU - Al-Chalabi, Ammar

PY - 2007/12

Y1 - 2007/12

N2 - Amyotrophic lateral sclerosis (ALS) is a severe clinical condition characterized by upper and lower motor neuron degeneration for which there is no truly effective treatment. The absence of an effective treatment can be explained in part by the complex and heterogeneous genetic, biochemical, and clinical features of ALS. While ALS accounts for the majority of the motor neuron diseases, the recognition of disease variants and mimic syndromes may lead to further insights into possible causes for the generality of ALS. From a biochemical perspective, the process of motor neuron degeneration is complex and the multifactorial influences and potential biomarkers of ALS have never been assessed in the light of the clinical heterogeneity of ALS. Several genes and environmental influences have been suggested as possible risk factors of ALS. A better understanding of interactions between these risk factors, potential biomarkers and heterogeneous clinical features may lead to more clearly defined pathological profiles among individuals or groups of ALS patients and in turn lead to more focused therapeutic trials.

AB - Amyotrophic lateral sclerosis (ALS) is a severe clinical condition characterized by upper and lower motor neuron degeneration for which there is no truly effective treatment. The absence of an effective treatment can be explained in part by the complex and heterogeneous genetic, biochemical, and clinical features of ALS. While ALS accounts for the majority of the motor neuron diseases, the recognition of disease variants and mimic syndromes may lead to further insights into possible causes for the generality of ALS. From a biochemical perspective, the process of motor neuron degeneration is complex and the multifactorial influences and potential biomarkers of ALS have never been assessed in the light of the clinical heterogeneity of ALS. Several genes and environmental influences have been suggested as possible risk factors of ALS. A better understanding of interactions between these risk factors, potential biomarkers and heterogeneous clinical features may lead to more clearly defined pathological profiles among individuals or groups of ALS patients and in turn lead to more focused therapeutic trials.

KW - Amyotrophic lateral sclerosis

KW - Biochemistry

KW - Epidemiology

KW - Genetics

KW - Heterogeneity

KW - Motor neuron disease

UR - http://www.scopus.com/inward/record.url?scp=37549000493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549000493&partnerID=8YFLogxK

U2 - 10.2174/092986707782793862

DO - 10.2174/092986707782793862

M3 - Article

VL - 14

SP - 3185

EP - 3200

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 30

ER -